Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Denver, Colorado

This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7451
Shown on this page
12
Local exact-city summaries
1093
Based on exact city/state matches in the local index.
Local exact-city recruiting
527
Live official results below use the broader ClinicalTrials.gov location search.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Denver, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1–12 of 7,451 matching trials in Denver, CO.
Live ClinicalTrials.gov results.
The summary panels count exact city/state matches in the stored directory for Denver, CO. The trial list uses ClinicalTrials.gov location matching when live results are available, which can differ from those local counts. No distance radius is applied; check each official record for its listed facilities. During an upstream outage, the list may use the clearly labeled local fallback.

Top conditions in local exact-city summaries

Multiple Myeloma 41 Breast Cancer 38 Advanced Solid Tumor 20 Malignant Solid Neoplasm 17 Colorectal Cancer 16 Ovarian Cancer 16

Top sponsors in local exact-city summaries

National Cancer Institute (NCI) 121 Alliance for Clinical Trials in Oncology 35 University of Colorado, Denver 34 ECOG-ACRIN Cancer Research Group 31 Janssen Research & Development, LLC 31 Children's Oncology Group 30

Top therapies in local exact-city summaries

Pembrolizumab 56 Cyclophosphamide 51 Carboplatin 49 Paclitaxel 41 Cisplatin 37 Nivolumab 37

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
19
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
Adagrasib, Pembrolizumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
220
States / cities
Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

NCT06159725
View directory record Official record
Conditions
Persistent Infection, Cystic Fibrosis
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 3 Interventional

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting No phase listed Observational

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions
No Intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
111
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

NCT07321678
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ASC30 tablets, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Riverside, California • San Jose, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06957080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Remigromig, Ranibizumab
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
107
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

NCT07541287
View directory record Official record
Conditions
IgA Nephropathy
Interventions
JADE101
Drug
Lead sponsor
Jade Biosciences, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Chula Vista, California • Arvada, Colorado • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT04666610
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 25 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069
View directory record Official record
Conditions
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
180 Days to 22 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
108
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Placebo, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT